Evidence map›Paper›PMID 41646370›Full record

ArticleResearch square2026

A Minimal Model Framework for Robust CAR-T Cell and Oncolytic Virus Combination Therapy.

Aisha Tursynkozha, Yang Kuang

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aisha TursynkozhaSchool of Artificial Intelligence and Data Science, Astana IT University, Astana, 010000, Kazakhstan.
Yang KuangSchool of Mathematical and Statistical Sciences, Arizona State University, Tempe, AZ, 85287, USA.ORCID 0000-0003-2774-4133

Funding

A wastewater approach to viral transmission, evolution, and ecologyR01AI192873 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Fuqing Wu · 2025 to 2026
$1.1M
NIAID NIH HHS R01 AI192873
6 · The paper itself

Abstract

Glioblastoma remains one of the most lethal brain cancers. Combination therapy using CAR-T cells and oncolytic viruses shows promise, yet mechanisms underlying synergy remain poorly understood. We develop mathematical models to analyze IL-13R

Indexed as

CAR-T therapyCombination therapyGlioblastomaMathematical modelingOncolytic virusTherapeutic synergy

Identifiers

PMID41646370
PMCPMC12869583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.